Related Experiment Video
Updated: Aug 4, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Hormonal treatment in prostate cancer
Endocrinologie
|January 1, 1991
Summary
Hormonal therapy for prostate cancer aims to reduce androgenic hormones. This review covers traditional and novel treatments, offering recommendations for their use in elderly men.
Area of Science:
- Oncology
- Endocrinology
- Urology
Background:
- Prostate cancer is a leading cause of mortality and morbidity in elderly men.
- Effective treatment necessitates accurate histologic diagnosis and staging of disease spread.
- Prostate cancer cells are often androgen-dependent, making hormonal therapy a key strategy.
Purpose of the Study:
- To review and provide recommendations on hormonal therapies for prostate cancer.
- To discuss the indications, administration, and effectiveness of various hormonal treatments.
- To cover both traditional and advanced therapeutic approaches.
Main Methods:
- Review of traditional hormonal therapies (e.g., orchidectomy, androgen administration).
- Evaluation of modern hormonal therapies (e.g., anti-androgens, GnRH analogs).
- Analysis of treatment effectiveness, indications, and administration routes.
Main Results:
- Hormonal therapy is crucial for androgen-dependent prostate cancer.
- A range of treatments exist, from surgical interventions to advanced pharmaceutical agents.
- Specific recommendations are provided for optimizing treatment outcomes.
Conclusions:
- Hormonal therapy is a cornerstone in managing prostate cancer, particularly in elderly men.
- The choice of therapy depends on disease stage and patient factors.
- Continued research and application of novel agents are vital for improving patient survival and quality of life.
Related Concept Videos
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...